Recent Updates
Recently added Catalysts
BFRI Neutral Sentiment Score: 60/100

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Monday, August 4, 2025 1 min read
Key Takeaway: Biofrontera Inc. announced that it will report its financial results for the second quarter of FY 2025 on August 13, 2025. The results will be released after market hours, followed by a conference call on August 14 to discuss the outcomes and business updates. The company specializes in dermatological products, particularly in the treatment of skin conditions. This reporting highlights the company's continuous engagement with stakeholders and its oversight of fiscal performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Biofrontera is reporting its financial results, indicating ongoing operations.
  • The company has a structured plan for a conference call to discuss results.

Full Press Release Details

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.
Conference Call and Webcast Information
Event: Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call
Date: Thursday, August 14, 2025
Time: 10:00am ET
Conference Call: 1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast: Webcast | Second Quarter 2025 Financial Results and Business Update Conference Call
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

Tags

biopharmaceutical company
dermatological products
Second Quarter FY 2025

Frequently Asked Questions

When will Biofrontera report its financial results?

Biofrontera will report financial results on August 13, 2025, after market close.

What is the date and time of the conference call?

The conference call is scheduled for August 14, 2025, at 10:00 am ET.

How can I join the conference call?

To join, call 1-877-877-1275 (U.S.) or 1-412-858-5202 (international).

What does Biofrontera specialize in?

Biofrontera specializes in dermatological products and photodynamic therapy.

What is Ameluz ® used for?

Ameluz ® is used for treating actinic keratosis and pre-cancerous skin lesions.

Tags: BFRI Viatris Investor Conferences Healthcare Biofrontera financial results dermatological products August 2025
Last updated: Aug 4, 2025